Health & Fitness
Wed, November 3, 2010Tue, November 2, 2010Mon, November 1, 2010Sat, October 30, 2010Fri, October 29, 2010Thu, October 28, 2010Wed, October 27, 2010Tue, October 26, 2010Mon, October 25, 2010Sun, October 24, 2010Sat, October 23, 2010Fri, October 22, 2010Thu, October 21, 2010Wed, October 20, 2010Tue, October 19, 2010Mon, October 18, 2010Sun, October 17, 2010Sat, October 16, 2010Fri, October 15, 2010BioSante Pharmaceuticals, Inc. To Present at Two Upcoming Investor Conferences
Published in Health and Fitness on Tuesday, October 26th 2010 at 5:11 GMT by Market Wire
LINCOLNSHIRE, Ill.--([ BUSINESS WIRE ])--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the Oppenheimer Healthcare Conference being held in New York on November 2-3, 2010, and the Singular Research Conference being held on November 4, 2010 in Los Angeles.
Stephen M. Simes, BioSantea�s president & chief executive officer, will speak on Wednesday, November 3, 2010 at 10:50 am ET at the Oppenheimer Healthcare Conference. Phillip B. Donenberg, BioSantea�s senior vice president of finance and CFO will present on Thursday, November 4, 2010 at 1:20 pm PT at the Singular Research Conference.
Messrs Simes and Donenberg will provide a status update on BioSantea�s lead program, LibiGel� (testosterone gel), in Phase III clinical studies for the treatment of female sexual dysfunction, as well as a general overview of BioSante. A live audio webcast of Mr. Simesa� remarks may be accessed at [ http://www.veracast.com/webcasts/opco/healthcare2010/86205557.cfm ] and a replay will be available at the same link.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSantea�s lead products include LibiGel� (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrina" (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSantea�s licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gela", a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLooka"), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: [ www.biosantepharma.com ].
